Conclusions and Award Ceremony

In the closing segment of this Cancer Network Face Off on advanced hepatocellular carcinoma (HCC), moderator and judge Rachna T. Shroff, MD, reflects on how dramatically the treatment landscape has expanded, recalling an era when sorafenib was the only systemic option. She notes that clinicians now have multiple effective frontline regimens, including atezolizumab plus bevacizumab, tremelimumab plus durvalumab, and nivolumab plus ipilimumab, and emphasizes that selecting among them depends on the individual patient. Shroff declares both Team Deep-Dish Pizza and Team Chicago Hot Dog winners, praising their command of the data and their illustration of multidisciplinary management in advanced HCC. She thanks the panelists for their thoughtful, clinically grounded discussion and the audience for joining the program. The conclusion reinforces the central theme that expanding frontline options have made patient-specific factors, liver function, and multidisciplinary input the drivers of treatment decisions in advanced HCC.